While most tumor immunotherapies aimed at harnessing the killing activity of CD8+ T cells, there is increasing evidence that CD4+ T cells also play a major role during antitumor immune response both in preclinical models and in patients with cancer1–9. Here, CD4 is linked to neoplasm.